Compare AEYE & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | RLYB |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 86.6M |
| IPO Year | 2011 | 2021 |
| Metric | AEYE | RLYB |
|---|---|---|
| Price | $8.05 | $16.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.63 | N/A |
| AVG Volume (30 Days) | ★ 60.3K | 25.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $40,311,000.00 | $858,000.00 |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $11.45 | N/A |
| P/E Ratio | ★ N/A | $2.75 |
| Revenue Growth | 14.52 | ★ 43.00 |
| 52 Week Low | $5.31 | $0.48 |
| 52 Week High | $16.39 | $17.57 |
| Indicator | AEYE | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.